Insmed Past Earnings Performance
Past criteria checks 0/6
InsmedDie Erträge des Sektors -18.6% sind im Durchschnitt pro Jahr zurückgegangen, während die Erträge des Sektors Biotechs growing auf 17.4% pro Jahr stiegen. Die Einnahmen sind growing mit einer durchschnittlichen Rate von 31.4% pro Jahr gesunken.
Key information
-21.0%
Earnings growth rate
-7.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 27.8% |
| Return on equity | n/a |
| Net Margin | -245.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 25
Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected
Dec 18Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely
Jul 28Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)
Jul 01Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?
Apr 18A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)
Feb 23Insmed inks financing agreements to raise $500M
Oct 19Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?
Oct 17An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued
Sep 20Insmed rises 16% on better-than-expected Q2 result
Aug 04Is Insmed (NASDAQ:INSM) A Risky Investment?
Jun 24Insmed: Temporarily Stuck
Feb 19Is Insmed (NASDAQ:INSM) Using Debt Sensibly?
Dec 11Is Insmed (NASDAQ:INSM) Using Too Much Debt?
Sep 10Estimating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)
Jun 10Insmed to raise $250M in stock offering, $500M in notes offering
May 10We Think The Compensation For Insmed Incorporated's (NASDAQ:INSM) CEO Looks About Right
May 06Is Insmed (NASDAQ:INSM) Weighed On By Its Debt Load?
Apr 06Have Insiders Been Selling Insmed Incorporated (NASDAQ:INSM) Shares?
Mar 02Revenue & Expenses BreakdownBeta
How Insmed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 305 | -750 | 345 | 571 |
| 30 Sep 23 | 281 | -724 | 328 | 559 |
| 30 Jun 23 | 269 | -696 | 313 | 549 |
| 31 Mar 23 | 257 | -547 | 289 | 441 |
| 31 Dec 22 | 245 | -482 | 266 | 398 |
| 30 Sep 22 | 242 | -434 | 257 | 349 |
| 30 Jun 22 | 221 | -416 | 242 | 320 |
| 31 Mar 22 | 201 | -438 | 239 | 296 |
| 31 Dec 21 | 188 | -435 | 234 | 273 |
| 30 Sep 21 | 174 | -424 | 225 | 264 |
| 30 Jun 21 | 171 | -375 | 211 | 235 |
| 31 Mar 21 | 168 | -319 | 204 | 221 |
| 31 Dec 20 | 164 | -294 | 204 | 181 |
| 30 Sep 20 | 169 | -245 | 198 | 90 |
| 30 Jun 20 | 164 | -242 | 205 | 111 |
| 31 Mar 20 | 151 | -247 | 207 | 79 |
| 31 Dec 19 | 136 | -254 | 211 | 132 |
| 30 Sep 19 | 101 | -293 | 215 | 202 |
| 30 Jun 19 | 62 | -320 | 206 | 155 |
| 31 Mar 19 | 32 | -330 | 190 | 151 |
| 31 Dec 18 | 10 | -324 | 168 | 145 |
| 30 Sep 18 | 0 | -298 | 146 | 55 |
| 30 Jun 18 | 0 | -256 | 119 | 49 |
| 31 Mar 18 | 0 | -224 | 98 | 45 |
| 31 Dec 17 | 0 | -193 | 79 | 110 |
| 30 Sep 17 | 0 | -196 | 60 | 37 |
| 30 Jun 17 | 0 | -188 | 56 | 38 |
| 31 Mar 17 | 0 | -180 | 52 | 36 |
| 31 Dec 16 | 0 | -176 | 51 | 35 |
| 30 Sep 16 | 0 | -139 | 51 | 34 |
| 30 Jun 16 | 0 | -132 | 49 | 30 |
| 31 Mar 16 | 0 | -124 | 46 | 27 |
| 31 Dec 15 | 0 | -118 | 43 | 23 |
| 30 Sep 15 | 0 | -105 | 39 | 24 |
| 30 Jun 15 | 0 | -98 | 36 | 24 |
| 31 Mar 15 | 0 | -92 | 34 | 18 |
| 31 Dec 14 | 0 | -79 | 31 | 23 |
| 30 Sep 14 | 0 | -78 | 29 | -3 |
| 30 Jun 14 | 0 | -71 | 25 | 19 |
| 31 Mar 14 | 0 | -57 | 25 | 16 |
| 31 Dec 13 | 0 | -56 | 22 | 15 |
| 30 Sep 13 | 0 | -55 | 18 | 37 |
Qualität der Erträge: INSM ist derzeit unrentabel.
Wachsende Gewinnspanne: INSM ist derzeit unrentabel.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Ergebnisentwicklung: INSM ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 18.6% pro Jahr zugenommen.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von INSM verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: INSM ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-42.7%) erschwert.
Return on Equity
Hohe Eigenkapitalrendite: INSMDie Verbindlichkeiten des Unternehmens übersteigen seine Vermögenswerte, so dass es schwierig ist, seine Eigenkapitalrendite zu berechnen.